VIDEO: Patient, doctor education support Xdemvy launch
Click Here to Manage Email Alerts
NEW YORK — Reimbursement and pipeline products, as well as educating patients and doctors about Demodex blepharitis, remain priorities for Tarsus Pharmaceuticals in the wake of Xdemvy’s launch, a company executive said at Vision Expo East.
“We recently shared that in the fourth quarter of 2023 we had 17,000 patients served by Xdemvy [lotilaner ophthalmic solution 0.25%],” Tarsus chief commercial officer Aziz Mottiwala, said in this Healio video. “Even more exciting is that 6,000 eye doctors have prescribed it for patients. It speaks to a need in the marketplace for a treatment for Demodex blepharitis.”
Mottiwala said the company’s recently launched “Mite Party” campaign focuses on encouraging patients to speak to their doctors about ocular discomfort that may be caused by Demodex.
In addition, Tarsus continues to work with payers “to make the prescribing process easy and affordable,” he said.
Mottiwala noted that Tarsus is in phase 2 studies for drugs for rosacea, meibomian gland dysfunction and the prevention of Lyme disease.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts